Apricot Capital
Apricot Capital is a Shanghai-based venture capital firm founded in 2015 that invests in early and growth-stage healthcare and life sciences companies across Asian and Western markets, with a portfolio focused on clinical-stage biotechnology and selective consumer bets.
- Company typePrivate
- Founded2015
- HeadquartersShanghai, China
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Apricot Capital does
Apricot Capital is a Shanghai-based venture capital investment firm founded in 2015 that focuses on early and growth-stage companies in the healthcare and life sciences sectors. The firm operates with a team of 11-50 employees and pursues a cross-border investment strategy, co-investing alongside prominent institutional investors including Pfizer Ventures, Qiming Venture Partners, HSG, Yuanbio Venture Capital, Highlight Capital, TF Capital, and Loyal Valley Capital. Its portfolio is anchored by clinical-stage and early-clinical biotechnology companies developing T-cell engager therapies and RNA-targeting therapeutics, including Vibrant Therapeutics (T-cell engagers for solid tumors, $100M total raised), Excalipoint Therapeutics (T-cell engagers for cancer and autoimmune diseases, $68.7M seed), and Vivatides Therapeutics (extrahepatic RNA-targeting therapeutics, $54M Series A).
The firm's business model is capital deployment into portfolio companies rather than product sales, with revenue derived from conventional VC mechanics: management fees on committed capital and carried interest on realized exits. Pricing models, fee rates, and fund vintages are not disclosed in the source material. Beyond its healthcare core, Apricot Capital has extended into consumer and lifestyle investments, exemplified by a seven-figure investment in Pop Padel, a Singapore-founded padel club expanding into Malaysia. Leadership comprises founding partner Weixiong Mao, co-founding partner Liu Wenyi, managing partners Haigang Chen and Arthur Qiang, and managing director Zhen Zhang. The firm also maintains an ISO/IEC 27001:2022 certification, signaling operational information-security discipline. Note: source material contains conflicting identity signals, including references to an Armenia-domiciled 'Apricot Capital CJSC' and a separate 'post-acute care' entity reportedly backed by Insight Partners; this description prioritizes the Shanghai-headquartered healthcare-focused identity consistent with the firmographics block and the bulk of disclosed investment activity.
Apricot Capital firmographics
Firmographics- Name
- Apricot Capital
- Legal name
- Apricot Capital CJSC
- Website
- https://apricot-capital.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Apricot Capital is a Shanghai-based venture capital firm founded in 2015 that invests in early and growth-stage healthcare and life sciences companies across Asian and Western markets, with a portfolio focused on clinical-stage biotechnology and selective consumer bets.
- Ownership category
- akta.pro rank
Apricot Capital industry classification
Industry- Product category
- Venture Capital
- NAICS
- Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)
Keywords
Where Apricot Capital is headquartered
LocationHeadquarters
- HQ city
- Shanghai
- HQ country
- China
- HQ region
- Asia
Markets served
Apricot Capital business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales
Apricot Capital product offering
Product offeringCore offering
Apricot Capital is a venture capital firm that invests equity capital in early-to-growing stage companies, primarily in the healthcare and life sciences sectors, with a portfolio that includes therapeutics developers such as Vibrant Therapeutics, Excalipoint Therapeutics, and Vivatides Therapeutics, plus selective non-healthcare deals such as Pop Padel. Beyond capital, the firm provides strategic guidance and network access to its portfolio companies. Founded in 2015 and headquartered in Shanghai, China, it operates with 11–50 employees.
Product overview
Apricot Capital is a venture capital firm that invests in growth-stage companies across sectors including biotechnology, healthcare, and technology. Based on the source material, Apricot Capital has made investments in multiple biotech companies including Vivatides Therapeutics (RNA therapeutics), Excalipoint Therapeutics (T-cell engager therapies), Vibrant Therapeutics (oncology drug development), and Pop Padel (sports/entertainment). The firm appears to focus on providing capital and strategic support to portfolio companies rather than offering a discrete technology product or platform.
Differentiator
Problem solved
Functional benefit
Products and services
- Venture Capital Investment (Healthcare and Life Sciences Focus) Equity capital investment in early-to-growing stage companies, with the firm's active portfolio concentrated in healthcare and life sciences (including therapeutics developers such as Vibrant Therapeutics, Excalipoint Therapeutics, and Vivatides Therapeutics). Provided to founders and boards of target portfolio companies raising growth equity.
- Growth Equity Investment Outside Healthcare Selective growth-equity investments outside the core healthcare thesis, exemplified by the Pop Padel investment. Provided to founders and boards of non-healthcare growth-stage companies.
Companies that use Apricot Capital
Customer profileSegments1 record
Ideal customer profiles1 record
Apricot Capital technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Apricot Capital partnerships and signals
Strategic signalScale indicators1 record
Recent moves4 records
Expansion highlights4 records
Apricot Capital competitors and assessment
Company assessmentDirect peers
- Qiming Venture Partners: China-headquartered venture firm with a dedicated healthcare/biotech franchise that has co-invested alongside Apricot in Vivatides Therapeutics. Direct overlap in Asia life-sciences investing and syndicate relationship make it the closest comparable peer.
- Loyal Valley Capital: Shanghai-based growth and venture investor with healthcare exposure, named as a recurring Apricot co-investor. Comparable cross-border China-focused fund with overlapping portfolio company base.
- Highlight Capital: Healthcare-focused venture and growth investor active in China and the US; participated alongside Apricot in Vivatides' Series A. Directly comparable by therapeutic focus and stage.
- TF Capital: China-based biotech-focused investor that co-invested with Apricot in Vivatides Therapeutics. Comparable in size, sector focus, and Chinese life-sciences mandate.
- Yuanbio Venture Capital: Chinese early-stage biotech investor that co-led Excalipoint Therapeutics' seed with Apricot. Closely comparable by stage, modality focus (T-cell engagers), and geography.
- OrbiMed: Global healthcare-dedicated investment firm covering venture through public markets. Comparable in therapeutic specialization, cross-border footprint, and life-sciences mandate.
- ARCH Venture Partners: US-based biotech-focused venture firm investing across modalities including T-cell engagers and RNA therapeutics. Comparable in stage and therapeutic focus; benchmark for what a scaled specialist VC in Apricot's niche can become.
Broad incumbents
- HSG (formerly Sequoia China): Large multi-stage China investor with a healthcare practice; co-led Excalipoint with Apricot. Larger and more diversified, but a meaningful comparator for institutional-grade China healthcare deployment.
- Bain Capital Life Sciences: Global life-sciences investment platform with venture, growth, and public strategies. Comparable cross-border biotech thesis, but materially larger AUM and broader mandate.
Others
- Pfizer Ventures: Corporate venture arm of Pfizer investing in early-stage biotech; co-invested with Apricot in Vibrant Therapeutics. Functions as a strategic capital partner and syndicate reference point rather than a direct competitor for ownership.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights6 records
Customer concentration
Apricot Capital financial estimates
Financial estimateRevenue estimate
Valuation estimate
Apricot Capital leadership team
Management profileNumber of profiles
Profiles6 records
Apricot Capital funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Apricot Capital M&A and investment
M&A and investmentM&A
Investments47 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Apricot Capital
What does Apricot Capital do?
Apricot Capital is a venture capital firm that invests equity capital in early-to-growing stage companies, primarily in the healthcare and life sciences sectors, with a portfolio that includes therapeutics developers such as Vibrant Therapeutics, Excalipoint Therapeutics, and Vivatides Therapeutics, plus selective non-healthcare deals such as Pop Padel. Beyond capital, the firm provides strategic guidance and network access to its portfolio companies. Founded in 2015 and headquartered in Shanghai, China, it operates with 11–50 employees.
Is Apricot Capital a public or private company?
Apricot Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Apricot Capital founded?
Apricot Capital was founded in 2015. It employs 11 to 50 people.
Where is Apricot Capital based?
Apricot Capital is headquartered in Shanghai, China, in the Asia region.
Who are Apricot Capital's main competitors?
Direct peers on record are Qiming Venture Partners, Loyal Valley Capital, Highlight Capital, TF Capital, Yuanbio Venture Capital, OrbiMed and ARCH Venture Partners. Broad incumbents are HSG (formerly Sequoia China) and Bain Capital Life Sciences. Pfizer Ventures is listed as an others.
Does Apricot Capital have an API?
No public API is recorded for Apricot Capital.
What industry is Apricot Capital in?
Apricot Capital's product category is Venture Capital. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 523940 and its SIC code is 6282.